Effect of metformin and Pioglitazone on insulin dose reduction in type 2 diabetes mellitus patients: An open level comparative prospective study

Goutameswar Mazumdar, Bikash Swaika, Anindya Dasgupta

.
Department of Pharmacology, Burdwan Medical College, Burdwan, India.

DOI: 10.4236/jdm.2012.21018                

Abstract

Insulin therapy cause weight gain and may increase its own requirement. Type 2 diabetes mellitus is associated with insulin resistance and affect both endogenous and exogenous insulin effect. Metformin and Pioglitazone, commonly used insulin sensitizers, have the potentiality of reducing the insulin dose, in Type-2 diabetes mellitus (T2DM) patients. This study was held to assess and compare such potentiality. 40 T2DM patients not controlled by diet, exercise and oral antidiabetic agents were selected for this study. Study had observed that Pioglitazone and metformin both significantly had reduced the dose of insulin. But metformin reduce the dose of insulin significantly more than that of Pioglitazone. Metformin had reduced the triglyceride, LDL-c, waist hip ratio significantly but modestly increased serum lactic acid and HDL-c. It can be concluded that co-administration of metformin with insulin is more beneficial in relation to the dose of insulin, waist hip ratio, and lipid modification when compare to Pioglitazone.

Keywords

Type 2 Diabetes Mellitus; Insulin Dose; Pioglitazone; Metformin

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Banting, F.M. and Best, C.H. (1922) The internal secretion of the pancreas. Journal of Laboratory and Clinical Medicine, 7, 256-271
[2]	Buse, J.B., Polonsky, K.S. and Burant, C.F. (2008) Type 2 diabetes mellitus. In: Kronenberg, H.M., Melmed, S., Polanski, K.S., Larsen and P.R., Eds., Williams Textbook of Endocrinology, 11th Edition, Saunders Elsevier, Philadelphia, 1329-1389.
[3]	Yki-Javimen, H., Kaupilla, M., Kujansuu, E., et al. (1992) Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. New England Journal of Medicine, 327, 1426-1433. doi:10.1056/NEJM199211123272005
[4]	Warram, J.H., Martin, B.C., Krowelski, A.S., et al. (1990) Slow glucose removal and hyperinsulinemia precede the development of type 2 diabetes in the offspring of diabetic parents. Annals of Internal Medicine, 113, 909-915.
[5]	Cheng, Y.Y.A. and Zinman, B. (2010) Principles of Insulin Therapy. In: Khan, C.R., Weir, G.C., King, G.L., Jacobson, A.M., Moses, A.C. and Smith, R.J., Eds. Joslin’s Diabetes Mellitus, 14th Edition, Wolters Kluwer(India) Pvt Ltd, New Delhi, 659-670.
[6]	The Diabetes Control and Complications Research Group (1995) Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care, 18, 1415-1427. doi:10.2337/diacare.18.11.1415
[7]	UKPDS group (1998) intensive blood glucose control with sulphonulureasor insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet, 352, 837-853.
[8]	Field, J.B. (1970) Chronic insuli resistance. Acta Diabetologica, 7, 220-242. doi:10.1007/BF01556784
[9]	Inoguchi, T., Xia, P., Kunisaki, M., et al. (1994) insulin effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. American Journal of Physiology, 267, E369-E379.
[10]	Fonseca, V., Graveline, J. and Nissel, J. (1998) Long term experience with troglitazone in combination with insulin type 2 diabetes mellitus. Diabetes, 47, A90(abt).
[11]	Relimpio, F., Pumer, A., Losado, F., et al. (1998) Adding metformin versus insulin dose increase in insulin treated but poorly controlled type2 diabetes mellitus. An open label randomized trial. Diabetic Medicine, 15, 997-1002.
[12]	Schwartz, S., Raskin, P., Fonsec, V., et al. (1998) Effect of troglitazone in insulin-treated patients with type 2 diabetes mellitus. New England Journal of Medicine, 338, 861-866. doi:10.1056/NEJM199803263381302
[13]	Henry, R.R. (1996) Glucose control and insulin resistance in non-insulin dependent diabetes mellitus. Annals of Internal Medicine, 124, 97-103.
[14]	Bailey, C.J. Metformin in therapy for diabetes mellitus and related disorders. 5th Edition, ADA, 235-253.
[15]	Lebovitz, H.E. Thiazolidinedione in therapy for diabetes mellitus and related disorders. 5th Edition, ADA, 260-272.
[16]	Torbay, N., Bracco, E., Geliebter, A., et al. (1985) Insulin increases body fat despite control of food intake and physical activity. American Journal of Physical, 258, R2120-R2144.